Cardiff Oncology (CRDF) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 11, 2026, at company headquarters in San Diego, CA.

• Shareholders will vote on four key proposals, including director elections and executive compensation.

• Proxy materials and the 2025 Annual Report are available online, with options for paper or email copies upon request.

Voting matters and shareholder proposals

• Election of six directors: Dr. James O. Armitage, Dr. Rodney Markin, Mani Mohindru, Ph.D., Gary W. Pace, Ph.D., Renee P. Tannenbaum, and Låle White.

• Ratification of BDO USA, P.C. as independent registered public accountants for fiscal year ending December 31, 2026.

• Approval of an amendment to the 2021 Omnibus Equity Incentive Plan, increasing shares issuable to 15,150,000 from 12,150,000.

• Advisory vote on the compensation of named executive officers.

• Board recommends voting "FOR" all nominees and proposals.

Board of directors and corporate governance

• Six director nominees are presented for election at the annual meeting.

• Dr. Rodney S. Markin serves as Chairman of the Board.